Radionuclide‐Labeled Microspheres for Radio‐Immunotherapy of Hepatocellular Carcinoma
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202300944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Sai Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinar…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Brachytherapy, including radioactive seed implantation (RSI) and transarterial radiation therapy embolization (TARE), is an important treatment modality for advanced hepatocellular carcinoma (HCC), but the inability of RSI and TARE to treat tumor metastasis and recurrence limits their benefits for patients in the clinic. Herein, indoleamine 2,3‐dioxygenase 1 (IDO1) inhibitors‐loaded alginate microspheres (IMs) are developed as radionuclide carriers with immunomodulatory functions to achieve effective radio‐immunotherapy. The size and swelling properties of IMs can be facilely tailored by adjusting the calcium source during emulsification. Small/large IMs(SIMs/LIMs) are biocompatible and available for RSI and TARE, respectively, after 177 Lu labeling. Among them, 177 Lu‐SIMs completely eliminated subcutaneous HCC in mice after intratumoral RSI. Moreover, in combination with anti‐PD‐L1, 177 Lu‐SIMs not only eradicate primary tumors by RSI but also effectively inhibit the growth of distant tumors, wherein the potent abscopal effect can be ascribed to the immune stimulation of RSI and the modulation of the tumor immune microenvironment (TIME) by IDO1 inhibitors. In parallel, LIMs demonstrate excellent embolization efficiency, resulting in visible necrotic lesions in the central auricular artery of rabbits, which are promising for TARE in future studies. Collectively, a versatile therapeutic agent is provided to synchronously modulate the TIME during brachytherapy for efficient radio‐immunotherapy of advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medic…
- Invasive Technology Department, The Affiliated Suzhou Hospital of Nanjing Medical University, Jiangsu, Suzhou, 215101, P. R. China.
ORCID-Profile: Guanglin Wang, Kai Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, S., Mu, C., Liu, T., Pei, P., Shen, W., Zhang, Y., Wang, G., Chen, L., & Yang, K. (2023). Radionuclide‐Labeled Microspheres for Radio‐Immunotherapy of Hepatocellular Carcinoma. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202300944
Vancouver
Yang S, Mu C, Liu T, Pei P, Shen W, Zhang Y, et al. Radionuclide‐Labeled Microspheres for Radio‐Immunotherapy of Hepatocellular Carcinoma. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202300944
BibTeX
@article{Yang2023,
author = {Yang, Sai and Mu, Chongjing and Liu, Teng and Pei, Pei and Shen, Wenhao and Zhang, Yanxiang and Wang, Guanglin and Chen, Lei and Yang, Kai},
title = {Radionuclide‐Labeled Microspheres for Radio‐Immunotherapy of Hepatocellular Carcinoma},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202300944}
}
EUVIMED